Imatinib API

Name	Imatinib
Chinese name	伊马替尼
Cas Number	152459-95-5
Source	India
Qualifications	USDMF/CEP/-/-/-

Imatinib mesylate (Gleevec) was developed by Novartis, and was first approved by the US Food and Drug Administration (FDA) on May 10, 2001 (trade name: Gleevec). Its development was successful It directly opened the door to the development of cancer-targeted therapies using kinases as anti-tumor targets, and opened the prelude to the era of small-molecule targeted drugs to treat cancer. Imatinib is the first-generation TKI drug, an oral tyrosine kinase inhibitor drug, and the first-line drug for the treatment of chronic myelogenous leukemia (CML), which can make the 10-year survival rate of CML patients reach 85%~90 %, which greatly prolongs the life cycle of patients and is known as the "life-saving medicine for chronic myelogenous leukemia." Public data shows that in 2016, the global sales of imatinib mesylate tablets exceeded 4 billion US dollars. In 2017, Gleevec was listed as a Class B drug in China's basic medical insurance catalog, and subsequently the drug was also included in the local medical insurance catalog.

Hot Tags: imatinib api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bemeprost API, Fulvestrant API, Deoxycholic Acid API, Cinacalcet Hydrochloride API, Linagliptin API, Letrozole API

• Previous: Metaxalone API
• Next: Paroxetine Hydrochloride API